Schizophrenia Research
Volume 115, Issue 2 , Pages 97-103 , December 2009

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)

  • Han Boter

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Department of Epidemiology (room FA 40), University Medical Centre Groningen, PO Box 30001, NL - 9700 RB Groningen, The Netherlands. Tel.: +31 50 3611808; fax: +31 50 3614493.
    • ,
  • Joseph Peuskens

      Affiliations

    • University Psychiatric Centre, Campus St. Jozef Kortenberg, Katholieke Universiteit Leuven, Leuven, Belgium
    • ,
  • Jan Libiger

      Affiliations

    • Department and Clinic of Psychiatry, Charles University Medical School and Faculty Hospital, Hradec Králové, Czech Republic
    • ,
  • W. Wolfgang Fleischhacker

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Michael Davidson

      Affiliations

    • Sheba Medical Center, Tel Hashomer, Israel
    • ,
  • Silvana Galderisi

      Affiliations

    • Department of Psychiatry, University of Naples SUN, Naples, Italy
    • ,
  • René S. Kahn

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • for the EUFEST study group

Received 3 March 2009 ,Revised 3 August 2009 ,Accepted 16 September 2009.

References 

  1. Andreasen NC, Carpenter W, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry. 2005;162:441–449
  2. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J. Clin. Psychiatry. 2006;67:1707–1712
  3. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry. 2006;163:743–745
  4. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007;89:129–139
  5. Emsley RA, Risperidone Working Group . Risperidone in the treatment of first episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. 1999;25:721–729
  6. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr. Res. 2005;78:147–156
  7. Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, et al. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST Study. Schizophr. Res. 2009;XX:XXX-XXX. SCHRES-D-09-00139
  8. Gerlach J, Korsgaard S, Clemmesen P, Lauersen AM, Magelund G, Noring U, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 1993;87:244–252
  9. Guy W. Clinical Global Impressions (CGI) scale. In:  Rush AJ,  Pincus HA,  First MB,  Blacker D,  Endicott J,  Keith SJ,  Phillips KA,  Ryan ND,  Smith GR,  Tsuang MT,  Widiger TA,  Zarin DA editor. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000;p. 100–102
  10. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry. 1995;166:654–659
  11. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097
  12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  13. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312:345–349
  14. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining ‘response’ in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007;32:1903–1910
  15. Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophr. Bull. 2008;34:275–285
  16. Pocock SJ. Clinical Trials: A Practical Approach. Chichester: Wiley; 1993;
  17. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59(suppl 20):22–33
  18. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr. Scand. 2006;113:91–95

PII: S0920-9964(09)00438-1

doi: 10.1016/j.schres.2009.09.019

Schizophrenia Research
Volume 115, Issue 2 , Pages 97-103 , December 2009

Article Tools

* Image Usage & Resolution